Eton Pharmaceuticals IncChange company Symbol lookupSelect an option...ETON Eton Pharmaceuticals IncLXRX Lexicon Pharmaceuticals IncBVS Bioventus IncTDS-U Telephone and Data Systems IncELEV Elevation Oncology IncFRZA Forza X1 IncSIEN Sientra IncPMGM Priveterra Acquisition CorpNVFY Nova LifeStyle IncGGIFF Garibaldi Resources CorpGo
Eton Pharmaceuticals, Inc. is a pharmaceutical company, which is developing, acquiring and commercializing products to address unmet needs in patients suffering from rare diseases. It has three commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase deficiency, and Betaine Anhydrous for the treatment of homocystinuria. It also has three additional product candidates in late-stage development. The Company is developing dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO hydrocortisone autoinjector for the treatment of adrenal crisis, and ET-400. Its dehydrated alcohol injection product candidate is under review for the treatment of methanol poisoning. Its ZENEO hydrocortisone autoinjector product candidate is a needle-free autoinjector under development for the treatment of adrenal crisis.
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.